Few would place Recursion Pharmaceuticals (NASDAQ: RXRX), a little-known biotech company, in the same league as these tech ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower in Wednesday’s after-hours session after the company announced a proposed offering of its common stock. What Happened: After the ...

At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...